Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) 是一种长链脂肪酸，抑制脂肪酸向细胞转运。Sulfosuccinimidyl oleate sodium 是一种有效且不可逆的线粒体呼吸链抑制剂。Sulfosuccinimidyl oleate sodium 结合小胶质细胞表面上的CD36受体。具有抗炎作用。
| 生物活性 | Sulfosuccinimidyl oleate sodium (Sulfo-N-succinimidyl oleate sodium) is a long chain fatty acid that inhibits fatty acid transport into cells. Sulfosuccinimidyl oleate sodium is a potent and irreversible inhibitor ofmitochondrial respiratory chain. Sulfosuccinimidyl oleate sodium binds theCD36 receptoron the surface of microglia. Anti-inflammatory effect[1][2]. |
体外研究
(In Vitro) | Sulfosuccinimidyl oleate (20 μM and 50 μM, 24 hours) alone does not alter the cellular viability. Exposure to 100 ng/ml LPS+5 ng/mL IFNγ modestly, yet significantly reduces the viability of the BV2 cells. Co-treatment with Sulfosuccinimidyl oleate prevents the LPS+IFNγ-induced reduction in the cell viability[1].
Sulfosuccinimidyl oleate (50 μM, 24 hours) co-treatment significantly reduces the LPS+IFNγ-induced expression of NOS2 and COX-2 in BV2 cells. Western blot analysis reveals a significant LPS/IFNγ-induced upregulation in the phosphorylated form of the p38, which is prevented by co-treatment with Sulfosuccinimidyl oleate (50 μM, 24 hours)[1].
Cell Viability Assay[1] | Cell Line: | BV2 cells | | Concentration: | 20 μM and 50 μM | | Incubation Time: | 24 hours | | Result: | Did not alter the viability of BV2 cells alone. Exposure of BV2 cells to 100 ng/mL LPS and 5 ng/mL IFNγ significantly reduced the viability of BV2 cells while simultaneous treatment with Sulfosuccinimidyl oleate prevented it. |
Western Blot Analysis[1] | Cell Line: | BV2 cells | | Concentration: | 50 μM | | Incubation Time: | 24 hours | | Result: | Drastically increased the levels of NOS2, COX-2, and P-p38/T-p38. |
|
体内研究
(In Vivo) | Sulfosuccinimidyl oleate (50 mg/kg; administered once by single oral gavage) significantly reduces the cortical ischemic infarct size compared to vehicle-treated controls in male BALB/cABom mice with pMCAo model. In addition, Sulfosuccinimidyl oleate at 50 mg/kg is suitable to see a beneficial effect after stroke[1].
| Animal Model: | 4-month-old male BALB/cABom mice with pMCAo model[1] | | Dosage: | 50 mg/kg | | Administration: | Administered once by single oral gavage | | Result: | Reduced brain damage following ischemia. Attenuated infarct size. |
|
| 分子量 | |
| 性状 | |
| Formula | |
| CAS 号 | |
| 运输条件 | Room temperature in continental US; may vary elsewhere. |
| 储存方式 | 4°C, sealed storage, away from moisture *In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture) |
| 溶解性数据 | In Vitro: DMSO : 62.5 mg/mL(129.78 mM;Need ultrasonic) 配制储备液 | 1 mM | 2.0765 mL | 10.3825 mL | 20.7650 mL | | 5 mM | 0.4153 mL | 2.0765 mL | 4.1530 mL | | 10 mM | 0.2076 mL | 1.0382 mL | 2.0765 mL |
*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80℃, 6 months; -20℃, 1 month (sealed storage, away from moisture)。-80℃ 储存时，请在 6 个月内使用，-20℃ 储存时，请在 1 个月内使用。 In Vivo: 请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照In Vitro方式配制澄清的储备液，再依次添加助溶剂： ——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；
以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶 1. 请依序添加每种溶剂： 0.5% Methylcellulose/saline water Solubility: 3.33 mg/mL (6.91 mM); Suspended solution; Need ultrasonic 2. 请依序添加每种溶剂： 50%PEG300 50% saline Solubility: 3.33 mg/mL (6.91 mM); Suspended solution; Need ultrasonic 3. 请依序添加每种溶剂： 10% DMSO 40%PEG300 5%Tween-80 45% saline Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.32 mM，饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。 4. 请依序添加每种溶剂： 10% DMSO 90%corn oil Solubility: ≥ 2.08 mg/mL (4.32 mM); Clear solution
此方案可获得 ≥ 2.08 mg/mL (4.32 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。 *以上所有助溶剂都可在本网站选购。
|
m.cnreagent.com